Traditional drug discovery is long, costly, and uncertain. VSI Technologies' Molecule 360(tm) platform transforms early-stage R&D by using AI to simulate molecular efficacy, toxicity, and development risk–reducing the need for trial-and-error experimentation.Why Molecule 360(tm)?
- Massive early attrition in pipeline development
- Limited predictive insight into compound success
- Regulatory delays due to safety issues
Platform
Capabilities
1. Molecular Property Prediction using neural networks2. Simulated ADME-Tox Profiling3. Target Affinity Scoring and Lead Optimization Models4. Knowledge Graphs of Public and Proprietary Data
Benefits Delivered
- 3x faster preclinical candidate screening
- Reduced development costs by 20-30%
- Improved regulatory readiness and documentation accuracy
Conclusion
Molecule 360(tm) redefines how innovation happens in pharma. VSI Technologies helps biopharma R&D move faster, safer, and smarter.
